ClinicalTrials.gg
CompletedNCT01663532Updated Feb 16, 2015Results posted

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

A Phase 3 interventional study of Aripiprazole IM Depot and Placebo in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 49 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-02-16.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
29th of 125
340 · median 130
Started
2012
with 3 others
Phase 3
34 of 126
1 open now
Registered
74th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 29th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2012, is one of 34 in phase 3, and was the 74th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the overall efficacy of aripiprazole intramuscular (IM) depot as acute treatment in subjects with schizophrenia.

The secondary purpose is to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for 12 weeks to adult subjects with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects 18 to 65 years of age, inclusive, at time of .
  • Subjects with a diagnosis of schizophrenia for at least 1 year as defined by criteria and confirmed by the MINI for Schizophrenia and Psychotic Disorders Studies.
  • Subjects with a stable living environment when not in hospital.
  • Subjects who would benefit from hospitalization or continued hospitalization for treatment of a current acute relapse of schizophrenia at trial entry.
  • Subjects who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by meeting BOTH of the following at screening and baseline:

    • Currently experiencing an acute exacerbation of psychotic symptoms accompanied by significant deterioration in the subject's clinical and/or functional status from their baseline clinical presentation with a Positive and Negative Syndrome Scale (PANSS) Total Score ≥ 80 AND
    • Specific psychotic symptoms on the PANSS as measured by a score of > 4 on each of the following items (possible scores of 1 to 7 for each item)

      • Conceptual disorganization (P2)
      • Hallucinatory behavior (P3)
      • Suspiciousness/persecution (P6)
      • Unusual thought content (G9)
  • Subjects who have received previous outpatient antipsychotic treatment at an adequate dose for an adequate duration and who showed a previous good response to such antipsychotic treatment (other than clozapine) in last 12 months.
  • Subjects with a history of relapse and/or exacerbation of symptoms when not receiving antipsychotic treatment, excluding current episode.
  • Subjects willing to discontinue all prohibited psychotropic medications to meet protocol required washouts prior to and during trial period.
  • less ≤ 40 kg/m2 (morbid obesity) at screening.
  • Subjects who are able to provide written informed consent.
  • Ability to understand the nature of trial and follow protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Sexually active males of who do not agree to practice 2 different methods of or remain abstinent during the trial and for 180 days after last dose of trial medication. Sexually active females of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 150 days after last dose of trial medication.
  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving IMP in this trial.
  • Subjects with improvement of ≥ 30% in total PANSS score between the screening and baseline assessments. - Subjects presenting with a first episode of schizophrenia - Subjects hospitalized for ≥ 30 days out of the last 90 days prior to screening visit. Subjects who have been hospitalized > 5 days for current acute episode at the time of screening visit
  • Subjects with schizophrenia who are considered resistant/ to antipsychotic treatment Subjects who have a history of response to clozapine treatment only.
  • Subjects with a current Axis I diagnosis other than schizophrenia Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder or mental retardation.
  • Subjects experiencing acute depressive symptoms within past 30 days that require treatment with an antidepressant.
  • Subjects with a significant risk of violent behavior; who represent a risk of committing suicide as indicated by any suicidal ideation within the last 1 month or any suicidal behaviors within the last year; or who present a serious risk of suicide.
  • Subjects with tardive dyskinesia,.
  • Subjects with severe akathisia.
  • Subjects who have met DSM-IV-TR criteria for substance abuse with past 3 months prior to screening or dependence within past 6 months; including alcohol and benzodiazepines, but excluding caffeine and nicotine.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
340 participants (actual)

Study arms

  • Experimental
    Aripiprazole IM Depot

    Aripiprazole IM Depot 400 mg, with allowed decrease to 300 mg for safety and return to 400 mg for efficacy if needed, every four weeks for 12 weeks

    Drug: Aripiprazole IM Depot

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score.

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 that indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The PANSS total score was the sum of the rating scores for 7 positive subscale items, 7 negative subscale items, and 16 general psychopathology subscale items from the PANSS panel. PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome). The primary statistical comparison was performed using the Mixed Model Repeated Measure (MMRM) approach.

    Time frame: Baseline to Week 10

Secondary outcomes

  1. Mean Change From Baseline to Endpoint in Clinical Global Impression-Severity Scale (CGI-S) Score.

    The severity of illness for each participants were rated using the CGI-S scale. The study physician were to answer the following question: "Considering your total experience with this particular population, how mentally ill is the patient at this time?" Response choices included were: 0= not assessed; 1= normal; not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.

    Time frame: Baseline to Week 10

  2. Mean Change From Baseline to Endpoint in PANSS Positive Subscale Score.

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline to Week 10

  3. Mean Change From Baseline to Endpoint in PANSS Negative Subscale Score.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline to Week 10

  4. Mean Change From Baseline to Endpoint in Personal and Social Performance Scale (PSP) Score.

    The PSP was a validated clinician scale that measured personal and social functionining in 4 domains: socially useful activities eg, work and study), personal and social relationships, self-care, disturbing and aggressive behaviours. Impairement in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval and the study physician's judgement to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

    Time frame: Week 10

  5. Mean Clinical Global Impression-Improvement Scale (CGI-I) Score at Endpoint.

    The severity of illness for each participants were rated using the CGI-S scale. The study physician were to answer the following question: "Considering your total experience with this particular population, how mentally ill is the patient at this time?" Response choices included were: 0= not assessed; 1= normal; not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.

    Time frame: Week 10

  6. Responder Rate Based on PANSS Total Score.

    Responder rate was defined as ≥30% reduction from Baseline in PANSS Total Score. PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Week 10

07

Results

Posted Feb 16, 2015

Participant flow

The trial was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of aripiprazole IM (intramuscular) depot as treatment for an acute episode of schizophrenia in adult participants. The trial was conducted in 55 sites.

Participant flow — Overall Study
MilestoneAripiprazole IM Depot 400/300mgPlacebo
Started168172
Completed9465
Not completed74107
Withdrew: Lost to follow-up910
Withdrew: Adverse event713
Withdrew: Met withdrawal criteria76
Withdrew: Physician decision11
Withdrew: Withdrawal by subject3517
Withdrew: Lack of efficacy1560

Outcome measures

PrimaryMean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score.

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 that indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The PANSS total score was the sum of the rating scores for 7 positive subscale items, 7 negative subscale items, and 16 general psychopathology subscale items from the PANSS panel. PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome). The primary statistical comparison was performed using the Mixed Model Repeated Measure (MMRM) approach.

Time frame:
Baseline to Week 10
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score.
Units on a scaleAripiprazole IM Depot 400/300mgPlacebo
Week 1 (N= 162, 167)-8.9 ± 0.9-5.0 ± 0.9
Week 2 (N= 144, 157)-15.2 ± 1.2-8.3 ± 1.2
Week 4 (N= 134, 140)-19.0 ± 1.4-9.8 ± 1.3
Week 6 (N= 126, 117)-21.5 ± 1.5-10.3 ± 1.5
Week 8 (N= 108, 96)-23.7 ± 1.6-9.7 ± 1.6
Week 10 (N= 99, 81)-26.8 ± 1.6-11.7 ± 1.6
Statistical analysis
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = 0.0005 (Kenward-Rodger degree of freedom was used to test the treatment effects and p-value was not adjusted as this is a primary efficacy endpoint.) · Mean difference (final values): -3.9 · 95% CI -6.1 to -1.7Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 1.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (Kenward-Rodger degree of freedom was used to test the treatment effects and p-value was not adjusted as this is a primary efficacy endpoint.) · Mean difference (final values): -7.0 · 95% CI -10.0 to -4.0Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 2.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (Kenward-Rodger degree of freedom was used to test the treatment effects and p-value was not adjusted as this is a primary efficacy endpoint.) · Mean difference (final values): -9.2 · 95% CI -12.8 to -5.6Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at week 4.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (Kenward-Rodger degree of freedom was used to test the treatment effects and p-value was not adjusted as this is a primary efficacy endpoint.) · Mean difference (final values): -11.1 · 95% CI -15.0 to -7.3Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 6.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (Kenward-Rodger degree of freedom was used to test the treatment effects and p-value was not adjusted as this is a primary efficacy endpoint.) · Mean difference (final values): -14.0 · 95% CI -18.4 to -9.6Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 8.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (Kenward-Rodger degree of freedom was used to test the treatment effects and p-value was not adjusted as this is a primary efficacy endpoint.) · Mean difference (final values): -15.1 · 95% CI -19.4 to -10.8Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 10.
SecondaryMean Change From Baseline to Endpoint in Clinical Global Impression-Severity Scale (CGI-S) Score.

The severity of illness for each participants were rated using the CGI-S scale. The study physician were to answer the following question: "Considering your total experience with this particular population, how mentally ill is the patient at this time?" Response choices included were: 0= not assessed; 1= normal; not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.

Time frame:
Baseline to Week 10
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Endpoint in Clinical Global Impression-Severity Scale (CGI-S) Score.
Units on a scaleAripiprazole IM Depot 400/300mgPlacebo
Week 1 (N= 162, 168)-0.4 ± 0.1-0.2 ± 0.1
Week 2 (N= 144, 157)-0.8 ± 0.1-0.4 ± 0.1
Week 4 (N= 134, 140)-1.0 ± 0.1-0.4 ± 0.1
Week 6 (N= 126, 117)-1.2 ± 0.1-0.5 ± 0.1
Week 8 (N= 108, 96)-1.3 ± 0.1-0.6 ± 0.1
Week 10 (N= 99, 81)-1.4 ± 0.1-0.6 ± 0.1
Statistical analysis
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = 0.0001 (After the comparison for primary efficacy endpoint was statistically significant, the comparison of change from Baseline in CGI severity score was conducted at same alpha level 0.05.) · Mean difference (final values): -0.3 · 95% CI -0.4 to -0.1Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 1.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (After the comparison for primary efficacy endpoint was statistically significant, the comparison of change from Baseline in CGI severity score was conducted at same alpha level 0.05.) · Mean difference (final values): -0.4 · 95% CI -0.6 to -0.2Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 2.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (After the comparison for primary efficacy endpoint was statistically significant, the comparison of change from Baseline in CGI severity score was conducted at same alpha level 0.05.) · Mean difference (final values): -0.6 · 95% CI -0.7 to -0.4Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 4.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (After the comparison for primary efficacy endpoint was statistically significant, the comparison of change from Baseline in CGI severity score was conducted at same alpha level 0.05.) · Mean difference (final values): -0.7 · 95% CI -0.9 to -0.5Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 6.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (After the comparison for primary efficacy endpoint was statistically significant, the comparison of change from Baseline in CGI severity score was conducted at same alpha level 0.05.) · Mean difference (final values): -0.7 · 95% CI -0.9 to -0.5Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 8.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 (After the comparison for primary efficacy endpoint was statistically significant, the comparison of change from Baseline in CGI severity score was conducted at same alpha level 0.05.) · Mean difference (final values): -0.8 · 95% CI -1.1 to -0.6Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 10.
SecondaryMean Change From Baseline to Endpoint in PANSS Positive Subscale Score.

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline to Week 10
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Endpoint in PANSS Positive Subscale Score.
Units on a scaleAripiprazole IM Depot 400/300mgPlacebo
Week 1 (N= 162, 167)-3.5 ± 0.3-2.1 ± 0.3
Week 2 (N= 144, 157)-5.7 ± 0.4-3.4 ± 0.4
Week 4 (N= 134, 140)-7.0 ± 0.5-3.9 ± 0.4
Week 6 (N= 126, 117)-8.2 ± 0.5-4.4 ± 0.5
Week 8 (N= 108, 96)-8.9 ± 0.5-4.1 ± 0.5
Week 10 (N= 99, 81)-10.0 ± 0.5-4.9 ± 0.5
Statistical analysis
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = 0.0006 · Mean difference (final values): -1.4 · 95% CI -2.1 to -0.6Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 1.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -2.3 · 95% CI -3.3 to -1.3Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 2.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -3.1 · 95% CI -4.3 to -2.0Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 4.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -3.8 · 95% CI -5.1 to -2.6Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 6.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -4.8 · 95% CI -6.2 to -3.4Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 8.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -5.1 · 95% CI -6.4 to -3.7Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 10.
SecondaryMean Change From Baseline to Endpoint in PANSS Negative Subscale Score.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline to Week 10
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Endpoint in PANSS Negative Subscale Score.
Units on a scaleAripiprazole IM Depot 400/300mgPlacebo
Week 1 (N= 162, 167)-1.6 ± 0.2-0.7 ± 0.2
Week 2 (N= 144, 157)-2.4 ± 0.3-1.2 ± 0.3
Week 4 (N= 134, 140)-3.1 ± 0.4-1.3 ± 0.4
Week 6 (N= 126, 117)-3.5 ± 0.4-1.3 ± 0.4
Week 8 (N= 108, 96)-4.0 ± 0.4-1.4 ± 0.4
Week 10 (N= 99, 81)-4.5 ± 0.5-1.6 ± 0.5
Statistical analysis
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = 0.0023 · Mean difference (final values): -0.9 · 95% CI -1.6 to -0.3Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 1.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = 0.0032 · Mean difference (final values): -1.2 · 95% CI -2.0 to -0.4Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 2.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = 0.0003 · Mean difference (final values): -1.8 · 95% CI -2.7 to -0.8Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 4.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -2.2 · 95% CI -3.2 to -1.3Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 6.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -2.6 · 95% CI -3.7 to -1.4Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 8.
  • Aripiprazole IM Depot 400/300mg vs Placebo · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -2.8 · 95% CI -4.1 to -1.6Difference in Least Square (LS) mean of change and 95% Confidence interval were derived from pair-wise comparison within MMRM at Week 10.
SecondaryMean Change From Baseline to Endpoint in Personal and Social Performance Scale (PSP) Score.

The PSP was a validated clinician scale that measured personal and social functionining in 4 domains: socially useful activities eg, work and study), personal and social relationships, self-care, disturbing and aggressive behaviours. Impairement in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval and the study physician's judgement to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

Time frame:
Week 10
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Endpoint in Personal and Social Performance Scale (PSP) Score.
Units on a scaleAripiprazole IM Depot 400/300mgPlacebo
Mean Change From Baseline to Endpoint in Personal and Social Performance Scale (PSP) Score.12.3 ± 1.25.2 ± 1.2
Statistical analysis
  • Aripiprazole IM Depot 400/300mg vs Placebo · ANCOVA · p = <.0001 · Mean difference (final values): 7.1 · 95% CI 4.1 to 10.1Difference in least square mean of change were derived from ANCOVA model.
SecondaryMean Clinical Global Impression-Improvement Scale (CGI-I) Score at Endpoint.

The severity of illness for each participants were rated using the CGI-S scale. The study physician were to answer the following question: "Considering your total experience with this particular population, how mentally ill is the patient at this time?" Response choices included were: 0= not assessed; 1= normal; not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.

Time frame:
Week 10
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression-Improvement Scale (CGI-I) Score at Endpoint.
Units on a scaleAripiprazole IM Depot 400/300mgPlacebo
Mean Clinical Global Impression-Improvement Scale (CGI-I) Score at Endpoint.2.7 ± 1.23.7 ± 1.3
Statistical analysis
  • Aripiprazole IM Depot 400/300mg vs Placebo · Cochran-Mantel-Haenszel · p = <.0001CMH raw mean scores differ test (Van Elteren test) controlling for pooled centers.
SecondaryResponder Rate Based on PANSS Total Score.

Responder rate was defined as ≥30% reduction from Baseline in PANSS Total Score. PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Week 10
Reported as:
Number · participants
Responder Rate Based on PANSS Total Score.
participantsAripiprazole IM Depot 400/300mgPlacebo
Responder Rate Based on PANSS Total Score.6024
Statistical analysis
  • Aripiprazole IM Depot 400/300mg vs Placebo · Cochran-Mantel-Haenszel · p = <.0001 · Mean difference (final values): 22.7 · 95% CI 12.9 to 32.4CMH test controlling by region (pooled sites).

Adverse events

Collected over Adverse events were monitored from ICF signed untill Follow-up 14 (± 2) days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole IM Depot 400/300mg—8/167 (4.8%)91/167 (54.5%)
Placebo—6/172 (3.5%)68/172 (39.5%)
Most frequent serious events
Most frequent serious events
EventAripiprazole IM Depot 400/300mgPlacebo
SchizophreniaPsychiatric disorders3/1673/172
Psychotic disorderPsychiatric disorders2/1672/172
ArthralgiaMusculoskeletal and connective tissue disorders1/1670/172
AgitationPsychiatric disorders1/1670/172
Substance abusePsychiatric disorders1/1670/172
Suicidal ideationPsychiatric disorders1/1670/172
HypotensionVascular disorders0/1671/172
Most frequent other events
Most frequent other events
EventAripiprazole IM Depot 400/300mgPlacebo
Weight increasedInvestigations28/16712/172
HeadacheNervous system disorders24/16728/172
AkathisiaNervous system disorders19/1676/172
ConstipationGastrointestinal disorders16/16712/172
DyspepsiaGastrointestinal disorders10/16711/172
AgitationPsychiatric disorders9/16711/172
CoughRespiratory, thoracic and mediastinal disorders10/16710/172
ToothacheGastrointestinal disorders9/1678/172
Injection site painGeneral disorders9/1671/172
SedationNervous system disorders9/1672/172

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole IM Depot 400/300mgPlaceboTotal
Mean42.1 ± 11.042.7 ± 10.942.4 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole IM Depot 400/300mgPlaceboTotal
Female383371
Male130139269
08

Study locations

49 sites
  • Little Rock, Arkansas 72201, United States
  • Springdale, Arkansas 72764, United States
  • Anaheim, California 92805, United States
  • Carson, California 90746, United States
  • Escondido, California 92025, United States
  • Long Beach, California 90806, United States
  • Long Beach, California 90813, United States
  • National City, California 91950, United States
  • Oakland, California 94612, United States
  • Oceanside, California 92056, United States
  • Pico Rivera, California 90660, United States
  • San Diego, California 92102, United States
  • San Diego, California 92123, United States
  • Santa Ana, California 92701, United States
  • Sherman Oaks, California 91403, United States
  • Denver, Colorado 80209, United States
  • Washington, District of Columbia 20016, United States
  • Bradenton, Florida 34208, United States
  • Ft. Lauderdale, Florida 33301, United States
  • Ft. Lauderdale, Florida 33308, United States
  • Ft. Lauderdale, Florida 33334, United States
  • Hollywood, Florida 33021, United States
  • Kissimmee, Florida 34741, United States
  • Orlando, Florida 32810, United States
  • Atlanta, Georgia 30308, United States
  • Hoffman Estates, Illinois 60169, United States
  • Lake Charles, Louisiana 70629, United States
  • Flowood, Mississippi 39232, United States
  • St. Charles, Missouri 63304, United States
  • St. Louis, Missouri 63118, United States
  • St. Louis, Missouri 63128, United States
  • St. Louis, Missouri 63141, United States
  • Marlton, New Jersey 08053, United States
  • Holliswood, New York 11423, United States
  • Dayton, Ohio 45417, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Charleston, South Carolina 29407, United States
  • Austin, Texas 78731, United States
  • Austin, Texas 78754, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75243, United States
  • Houston, Texas 77007, United States
  • Salt Lake City, Utah 84106, United States
  • Popovaca, 44317, Croatia
  • Zagreb, 10090, Croatia
  • Daugavpils, LV-5417, Latvia
  • Jelgava, LV-3008, Latvia
  • Liepaja, LV-3401, Latvia
  • Strenci, LV-4730, Latvia
09

References and documents

Publications

  • Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, Perry PP, Gara M, McQuade RD, Carson WH, Sanchez R. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014 Nov;75(11):1254-60. doi: 10.4088/JCP.14m09168. PubMed 25188501 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 6 months after primary completion. A results delay was requested in Oct 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2012
First posted
Aug 13, 2012
Start
Oct 2012
Primary completionActual
Aug 2013
CompletionActual
Sep 2013
Results delay requested
Oct 10, 2014
Results first posted
Feb 16, 2015
Last update
Feb 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01663532
Responsible party
Sponsor
First posted
Aug 13, 2012
Start date
Oct 2012
Primary completion
Aug 2013
Completion
Sep 2013
Results posted
Feb 16, 2015
Last update
Feb 16, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion